Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2015 · 10-Q
Revenue$763.86K$763.86K−32.0% vs Q1 2014 Net Income-$1.20M-$1.20MN/M vs Q1 2014 EPS Diluted-$0.12-$0.12N/M vs Q1 2014 Operating Income-$1,149,999N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Free Cash Flowderived-$858,850N/M Margins · derivedOperating margin-150.6%−127.3 pt vs Q1 2014
Net margin-157.3%−100.9 pt vs Q1 2014
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end